Statin therapy for primary prevention of cardiovascular disease

JAMA

Volumn 310, Issue 22, 2013, Pages 2451-2452

  Taylor, Fiona C ^a   Huffman, Mark ^b   Ebrahim, Shah ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY BYPASS SURGERY; DRUG COST; DRUG EFFECT; DRUG TOLERABILITY; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; NOTE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES; EVIDENCE BASED MEDICINE; MORTALITY; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84889839579     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.281348     Document Type: Note

References (9)

1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816.
2. Cholesterol Treatment Trialists (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease. Lancet. 2012;380(9841):581-590.
3. National Institute for Health and Clinical Excellence (NICE). Technology Appraisal TA94. http://www.nice.org.uk/TA094. 2006. Accessed October 23, 2013.
4. Stagnitti MN. Trends in statins utilization and expenditures for the US civilian noninstitutionalized population, 2000 and 2005. http://meps.ahrq.gov/ mepsweb/data-files/publications/st205/stat205.pdf. Accessed October 23, 2013.
5. The Health and Social Care Information Centre. Prescriptions dispensed in the community. https://catalogue.ic.nhs.uk/publications/prescribing/primary/ pres-disp-com-eng-2001-11/pres-disp-com-eng-2001-11-rep.pdf. Accessed October 23, 2013.
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):S1-S113.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
8. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion. Arch Intern Med. 2012;172(15):1180-1182.
9. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults [published online ahead of print November 12, 2013]. Circulation. 2013. doi:10.1161/01.cir.0000437738.63853.7a.